Additional biomarkers were also identified with an increased risk of development of bone metastases, e.g., nuclear p65 expression [10] and CCN3 [11], and the ability to predict PC specific mortality, such as nuclear p65 expression [10] and neutral endopeptidase CD10 [12]. This evidence concerns the gene MME and pachyonychia congenita.